AZD5718 is an orally active inhibitor of FLAP (5?Lipoxygenase activating protein), with an IC50 of 2 nM. AZD5718 is used in the study for coronary artery disease[1].
AZD5718 demonstrates a dose dependent and greater than 90% suppression of leukotriene production over 24 h[1].AZD5718 exhibits an IC50 of 39 nM for LTB4[1].
AZD5718 exhibits t1/2 of 0.45 h and 2.1 h in rat and dog by iv injection, respectively[1].
[1]. Daniel Pettersen, et al. Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease. J Med Chem. 2019 May 9;62(9):4312-4324.